Pyrazolo[1,5-a]pyrazine Derivatives for mGluR2/3 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel compounds that exhibit negative allosteric modulation against Group II metabotropic glutamate receptors, specifically metabotropic glutamate receptor subtype 2 (mGluR2) and subtype 3 (mGluR3), to treat diseases associated with these receptors, as existing compounds do not effectively target these subtypes.
Innovation Solution
A compound of Formula (1), or its pharmaceutically acceptable salt, is developed, which includes specific structural elements such as R1, R2, R3, R4, R5, R6, Ra, Rb, Rc, Rd, Re, and X, forming a 6,7-dihydropyrazolo[1,5-a]pyrazinone derivative, that modulates Group II mGlu receptors, providing therapeutic and preventive agents for diseases involving these receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used to target mGluR2 and mGluR3 subtypes, then the structural requirements are met, but the subtype selectivity and therapeutic effectiveness are insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the phenyl ring (R3-R6) and heterocyclic group (Ring A) to create localized interactions with mGluR2/3 subtypes. The systematic variation of substituents at specific locations enables subtype-selective binding while maintaining overall molecular framework integrity.
Solution Approach 2:
The patent employs parameter changes by systematically modifying physical-chemical properties of substituents (electron-withdrawing/donating groups, steric bulk, hydrophobicity) at key positions to optimize binding affinity and selectivity for mGluR2/3 subtypes, thereby enhancing therapeutic effectiveness.
2Reliability
If novel compound structures are developed to improve mGluR2/3 modulation, then the therapeutic potential increases, but the synthesis complexity and manufacturing difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional modules: a core phenyl ring structure, heterocyclic groups (Ring A), and variable substituent positions (R1-R6). This modular architecture allows independent optimization of each segment for both biological activity and synthetic accessibility.
Solution Approach 2:
The patent employs universality by designing a core molecular framework that can accommodate multiple substituent variations while maintaining the fundamental mGluR2/3 modulation mechanism. This universal scaffold enables a series of analogs to be synthesized from common intermediates, reducing overall manufacturing complexity.
Data Source
AI summary
A process for preparing a compound of Formula (1a):or a pharmaceutically acceptable salt thereof.